CollPlant has signed a non-binding term sheet with a US company in the field of orthobiologics for the further development, potential commercialisation and supply of a novel absorbable bio-active surgical matrix intended for use in spinal fusion and trauma applications.
The new matrix is composed of CollPlant’s type 1 recombinant human collagen and synthetic minerals that mimic bone structure, and may be used in combination with bio-functional molecules.
CollPlant says that its rhCollagen is identical to the type I collagen produced by the human body, and has significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity, and reduced risk of immune response and transmission of diseases. These rhCollagen attributes, CollPlant believes, make it suitable for numerous tissue repair applications throughout the human body.
CollPlant estimates the size of the worldwide target market for relevant spinal and trauma treatments at US$3.5bn per annum. Yehiel Tal, chief executive officer of CollPlant, noted, “This agreement represents recognition of the value of our proprietary rhCollagen technology and biomaterials knowhow, and, over time, should help to catapult CollPlant to the forefront of the orthopaedic market.”
If an agreement is reached, and upon successful completion of the milestones of the agreement, CollPlant will receive payments for the license to use its technology, milestones for the achievement of clinical and regulatory events and single-digit royalty payments for future global sales, as well as participation in costs associated with the building of a CollPlant-run manufacturing facility for the production of rhCollagen and the product in the USA.
While there is no certainty of concluding a definitive agreement, both parties are pursuing its completion.